Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.

Literature DB >> 23246507

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.

Harel Dahari, Scott J Cotler, Thomas J Layden, Alan S Perelson.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Interleukins

Year: 2012 PMID： 23246507 PMCID： PMC3667977 DOI： 10.1016/j.jhep.2012.08.029

Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083

× No keyword cloud information.

10 in total

1. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors: A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal: Science Date: 1998-10-02 Impact factor: 47.728

2. Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors: Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal: Sci Transl Med Date: 2010-05-05 Impact factor: 17.956

3. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.

Authors: Harel Dahari; Evaldo S Affonso de Araujo; Bart L Haagmans; Thomas J Layden; Scott J Cotler; Antonio A Barone; Avidan U Neumann
Journal: J Hepatol Date: 2010-05-27 Impact factor: 25.083

4. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.

Authors: Andrew H Talal; Ruy M Ribeiro; Kimberly A Powers; Michael Grace; Constance Cullen; Musaddeq Hussain; Marianthi Markatou; Alan S Perelson
Journal: Hepatology Date: 2006-05 Impact factor: 17.425

5. Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

Authors: Evaldo Stanislau Affonso de Araujo; Harel Dahari; Scott J Cotler; Thomas J Layden; Avidan U Neumann; Carlos Eduardo Melo; Antonio Alci Barone
Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731

6. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.

Authors: Charles D Howell; Alexis Gorden; Kathleen A Ryan; Alexander J Thompson; Chadi Ibrahim; Michael Fried; Nezam H Afdhal; John G McHutchison; Kevin V Shianna; David B Goldstein; Alan R Shuldiner; Braxton D Mitchell
Journal: J Hepatol Date: 2011-10-23 Impact factor: 25.083

7. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.

Authors: Eva Herrmann; Jung-Hun Lee; George Marinos; Marlene Modi; Stefan Zeuzem
Journal: Hepatology Date: 2003-06 Impact factor: 17.425

8. Triphasic decline of hepatitis C virus RNA during antiviral therapy.

Authors: Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal: Hepatology Date: 2007-07 Impact factor: 17.425

9. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.

Authors: Harel Dahari; Marianthi Markatou; Marija Zeremski; Ivan Haller; Ruy M Ribeiro; Teresa Licholai; Alan S Perelson; Andrew H Talal
Journal: J Hepatol Date: 2007-02-22 Impact factor: 25.083

10. Antiviral action of ribavirin in chronic hepatitis C.

Authors: Jean-Michel Pawlotsky; Harel Dahari; Avidan U Neumann; Christophe Hezode; Georgios Germanidis; Isabelle Lonjon; Laurent Castera; Daniel Dhumeaux
Journal: Gastroenterology Date: 2004-03 Impact factor: 22.682